Амихай Меерович

Научные публикации

• Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine Tumors: A Brief Report
• Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response
• PTX Treatment of Colon Cancer: Mode of Action Based on Tumor Marker and Cytokine Kinetics
• Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance
• Macrophages Upregulate Estrogen Receptor Expression in the Model of Obesity-Associated Breast Carcinoma
• Prognostic Factors in Advanced Adrenocortical Carcinoma: Summary of a National Referral Center's 20 years of Experience
• Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
• A Rare Case of Cutaneous Metastasis of Bladder Transitional Cell Carcinoma
• Thyroid Hormones and Morphological Features of Primary Breast Cancer
• Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I)
• Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study
• Multimodality Treatment for Advanced Cervical Cancer With Isolated Metastasis to Interventricular Septum of the Heart
• RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS - IMPROVEMENTS IN THE PROTOCOL FOR MEASUREMENT OF PATIENT RADIATION EXPOSURE
• Modified bi-weekly cetuximab-cisplatin and 5-FU/leucovorin based regimen for effective treatment of recurrent/metastatic head and neck squamous cell carcinoma to reduce chemotherapy exposure of patients
• Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
• Transurethral Prostatectomy Before or After External Beam Radiotherapy: Complications and Reoperation Rates
• The potential of somatostatin receptor 2 as a novel therapeutic target in salivary gland malignant tumors
• Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in ⁶⁸Ga-DOTATATE PET/CT studies?
• Clinical Applicability of the Proliferation Marker Thymidine Kinase 1 in Head and Neck Cancer Patients
• Elevated Free Triiodothyronine Is Associated With Increased Proliferative Activity in Triple-negative Breast Cancer
• Assessment of jaw osteonecrosis diagnostic criteria in cancer patients with a history of radiation therapy and exposure to bone-modifying agents
• Dichotomic role of heparanase in a murine model of metabolic syndrome
• Trimodal therapy in T2-4aN0M0 bladder cancer--How to select the best candidate?
• Long-term outcomes in MEN-1 patients with pancreatic neuroendocrine neoplasms: an Israeli specialist center experience
• Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
• Endovascular brachytherapy for extensive right-heart and pulmonary artery sarcoma - a case report
• Regulation of Heparanase in Diabetes-Associated Pancreatic Carcinoma
• Authors' Response to the Letter by Lamarca et al. Entitled "Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration" Regarding "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms"
• Diffusion weighted magnetic resonance imaging of pre and post treatment nasopharyngeal carcinoma
• Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
• Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
• Predictive power of the post-treatment scans after the initial or first two courses of [¹⁷⁷Lu]-DOTA-TATE
• Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
• Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
• Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group Study
• Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience
• Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
• Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients
• Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma
• Heparanase augments insulin receptor signaling in breast carcinoma
• PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer
• The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients
• Evaluation of Clinical and Pathologic Risk Factors May Reduce the Rate of Multimodality Treatment of Early Cervical Cancer
• Novel high dose rate lip brachytherapy technique to improve dose homogeneity and reduce toxicity by customized mold
• Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: a case-control study
• Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme
• Integration of PET/CT into the preoperative evaluation of patients with early cervical cancer does not decrease the proportion of patients with positive lymph nodes found after surgery
• Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy
• Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma
• Versatile role of heparanase in inflammation